Patient-funded biotech in $100 million funding deal for DMD drug

(Reuters) - Akashi Therapeutics Inc, a U.S.-based biotech funded by DMD patient foundations, said it would get up to $100 million under a partnership with Germany's Grunenthal SA for developing a drug for the muscle-wasting disorder.

http://ift.tt/xePdMM

from Reuters: Health News
via animenewspro